Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
June 18, 2019 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics
June 13, 2019 08:42 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, June 13, 2019 (GLOBE NEWSWIRE) -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
Amarantus to Present at 9th Annual LD Micro Invitational Conference
June 04, 2019 13:39 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
Amarantus Releases Letter to Shareholders
May 31, 2019 11:01 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Emerging Legal Hemp Industry
May 28, 2019 09:30 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
January 17, 2019 07:00 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development...
MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa
January 15, 2019 07:00 ET
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Jan. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development...
Amarantus Provides 2019 Roadmap
January 07, 2019 08:00 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company...
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
November 28, 2018 07:55 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK and WEXFORD, Pa., Nov. 28, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Coeptis Pharmaceuticals, Inc., a diversified commercial biopharmaceutical company, today announced that it has entered...
Amarantus Provides Corporate Update
July 20, 2018 08:17 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company...